Objective:
Part A - Dose Escalation Phase of CM24 in Combination with Nivolumab
Primary Objectives
- To assess the safety, tolerability and the maximum tolerated dose (MTD) of CM24 in combination with 480mg nivolumab in adults with selected recurrent or metastatic solid tumors.
- Determine the recommended Phase 2 dose level (RP2D) of CM24 in combination with nivolumab
Part B - Expansion Phase of CM24 in combination with nivolumab in patients with NSCLC
Primary Objective
- To assess the efficacy of the recommended phase 2 dose (RP2D) of CM24 in combination with nivolumab in adults with immune-checkpoint refractory recurrent or metastatic NSCLC based on Objective Response Rate (ORR).
Part C - Expansion Phase of CM24 in combination with nivolumab and nab-paclitaxel in patients with pancreatic adenocarcinoma
Primary Objective
- To assess the efficacy of CM24 in combination with nivolumab and nab-paclitaxel in adults with metastatic pancreatic cancer based on Objective Response Rate.